A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment

Vinay S Eligar1
Stephen C Bain2
1University Hospital of Wales, Cardiff, UK; 2Singleton Hospital, Swansea University, Swansea, UK

Correspondence: Vinay S Eligar
University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK
Tel +44 780 911 8031
Email eligars@gmail.com

Abstract: Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose reductions. Overall, cardiovascular outcomes are no different from other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in clinical practice and emphasized its use in various stages of chronic kidney disease.

Keywords: sitagliptin, CKD, chronic kidney disease, renal impairment

Introduction
Current estimates suggest that by 2030 the worldwide prevalence of diabetes will be 336 million. In the UK, 3 million people1 are currently diagnosed with diabetes, and the numbers are set to rise. A UK-based study showed that diabetes prevalence increased from 2.8% in 1996 to 4.3% in 2005, predominantly due to an increase in type 2 diabetes mellitus (T2DM).2 In the US, about 18.8 million people have diabetes, and it is estimated that 7.0 million people are undiagnosed – this equates to 8.3% of the population.3

The aim of treatment in managing diabetes is to achieve good glycemic control and to reduce microvascular and macrovascular complications of diabetes. Apart from lifestyle modifications and dietary intervention, metformin is the first-line medical therapy in T2DM.4,5 Other agents like sulfonylurea, thiazolidinedione, α-glucosidase inhibitors, dipeptidylpeptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and insulin are used based upon individual requirements. This practice will probably change if early introduction of newer agents like DPP-4 inhibitors and GLP-1 analogs are demonstrated to achieve greater metabolic benefit in future studies. Pivotal studies like the Diabetes Control and Complications Trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC) study, and United Kingdom Prospective Diabetes Study (UKPDS) have demonstrated benefits of achieving lower glycated hemoglobin (HbA1c). Recently, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial showed that intensive glycemic control reduced development of macroalbuminuria.6 The major risk of intensive management is hypoglycemia. Attaining ideal control without any
hypoglycemia is a challenge. The presence of complications such as nephropathy further increases the hypoglycemia risk. Diabetic nephropathy also mandates the reduction or withdrawal of certain therapeutic agents. Recent studies have demonstrated a low risk of hypoglycemia with DPP-4 inhibitors in the absence of concomitant use of sulfonylureas or insulin. It has also found that appropriate dose reductions with sitagliptin and saxagliptin allow for their use in chronic kidney disease (CKD) stage 1–5 and end-stage renal disease (ESRD) on hemodialysis. Further to this, the improvements in β-cell function shown in the studies until now are also an advantage that can be derived by early use of sitagliptin.

**CKD and diabetes**

Several studies have established that diabetes is associated with a significantly increased risk for CKD. More recently, a UK-based study indicated that diabetes increases the risk of developing moderate to severe CKD (stages 3b, 4, and 5). In women, the risk was about eight times higher and in men over 12 times higher compared with those without diabetes.

Kidney failure is the final stage of CKD, and each year in the US more than 100,000 people are diagnosed with kidney failure or ESRD. Diabetes is the most common cause of ESRD, accounting for nearly 44% of new cases. CKD is now defined according to the parameters shown in Table 1.

Recently, there has been a wide debate regarding CKD classification. Following a collaborative meta-analysis and international conference by the organization Kidney Disease: Improving Global Outcomes (KDIGO), new recommendations for including clinical diagnosis and albuminuria stages, in addition to estimated glomerular filtration rate (eGFR) stages, are proposed. Tonelli et al have presented the new classification, integrating the new recommendations, which will help in making clinical decisions in order to improve patient outcomes.

Managing diabetes in the presence of CKD poses challenges, as CKD independently increases cardiovascular risk and mortality rates. The health burden in terms of cost of managing CKD and ESRD requiring renal replacement therapy is enormous. The goal is optimal glycemic control tailored to the patient. The availability of newer incretin-based therapies over the past 6 years has given a new dimension and opportunity in effective management of diabetes and associated metabolic syndrome. The management of T2DM in the presence of CKD is challenging. The risk of hypoglycemia and drug accumulation means that the choice of antidiabetic agents is narrowed, and dose reduction is advised. Making judicious use of newer therapies will help achieve better glycemic control and lower the complication rates. DPP-4 inhibitors have been licensed for use in this situation, even in CKD stage 3, stage 4, or stage 5 (ESRD) on hemodialysis. The pharmacokinetics of various DPP-4 inhibitors is different, and their suitability in CKD is variable. It is found that appropriate dose reductions with sitagliptin and saxagliptin allow for their use in all stages of CKD and ESRD on hemodialysis. Linagliptin is the only DPP-4 inhibitor licensed to be used without any dose reduction.

**β-cell dysfunction and development of diabetes**

T2DM is of multifactorial origin. The pathogenesis is complex and results from disturbance in insulin secretion, hepatic glucose production, and insulin resistance. Insulin is released from β-cells of the pancreas in a glucose-dependent manner via the action of incretins (GLP-1, gastric inhibitory peptide) secreted in response to oral carbohydrate. Obesity, insulin resistance, and genetic predisposition lead to disturbances in glucose regulation. The inadequate uptake of glucose from peripheral tissues leads to hyperglycemia and compensatory insulin hypersecretion from islet cells. Over a prolonged period of time, overburdened β-cells begin to dysfunction, and glycemic control worsens, leading to diabetes. The UKPDS has clearly demonstrated the progressive nature of β-cell dysfunction and the increasing need to add on further agents after a few years of treatment with sulfonylureas. Therapies that aim to conserve β-cells and protect them would be ideal in preventing progression of diabetes. Incretin-based treatment has been shown to be effective in protecting and preserving β-cell function in animal models. Experimental studies on diabetic mice models have also demonstrated improvement in islet cell mass, which means DPP-4 inhibitors may prevent β-cell dysfunction. However, this is still unproven in humans.

The human pancreas has pancreatic progenitor cells with the potential to transform into islet cells. In animal studies, diabetic mice treated with sitagliptin showed significant improvements in fasting glucose, HbA1c, islet cell mass, and ratio of pancreatic α-cells to β-cells. In contrast, the diabetic mice models treated with glipizide showed improved glycemic control in early weeks only and had no beneficial effects on glucagon or fasting glucose.

Transgenic mice with β-cell overexpression of human islet amyloid polypeptide, reduced β-cell mass, and altered islet cell topography showed improvements in islet cell topography and improved glucose-induced insulin
response following treatment with another DPP-4 inhibitor (vildagliptin). 19

Williams-Herman et al 20 also showed that 24 weeks of initial treatment with sitagliptin or metformin monotherapy improved β-cell function. Furthermore, the combination of the two agents showed greater improvements than the individual monotherapies.

Various clinical trials have evaluated changes in markers of β-cell function as part of their outcomes. Sitagliptin has shown encouraging results with improvements in baseline fasting glucose, insulin, C-peptide, and glucagon levels; homoeostasis model assessment: insulin resistance (HOMA-IR) and β-cell function (HOMA-β); and insulinogenic index (defined as 30–0 min insulin/30–0 min glucose). The biggest improvements are seen in recently diagnosed T2DM, as the β-cell function is not exhausted, in contrast to patients with many years of insulin resistance and hyperglycemia. Brazg et al 17 conducted a trial of the effect of sitagliptin when added on to ongoing metformin therapy. The trial group received sitagliptin 50 mg twice daily for 4 weeks followed by placebo, or vice versa. Sitagliptin treatment reduced 24-hour mean weighted plasma glucose. Fasting glucose and C-peptide levels also improved, suggesting a positive effect on β-cell function. Hence, markers of β-cell function (HOMA-β and proinsulin/insulin ratio) were improved with sitagliptin treatment. 21,22 This is an important aspect of treatment in T2DM, as it directly targets one of the major causes of the pathogenesis in T2DM. Hence, DPP-4 inhibitors have shown promising results in these initial studies. However, long-term studies specifically looking into improved β-cell function will be needed to ascertain whether the beneficial effect of DPP-4 persists beyond the initial years of treatment.

### Incretin-based therapy

In the last 6 years, incretin-based treatment has contributed to reshaping the paradigm for the management of T2DM. GLP-1 is a gut hormone produced by L-cells present in the small intestine. It is released in response to ingestion of food and exerts its effects to regulate glucose utilization. It acts by glucose-dependent insulin release, delayed gastric emptying, and inhibition of glucagon production. 23–25 The net effect is reduction in postprandial hyperglycemia due to glucose-dependent insulin release and suppression of glucagon production, leading to less hepatic glycolysis. In this way, it helps in regulating postprandial plasma glucose excursions and fasting hyperglycemia. GLP-1
is susceptible to dipeptidyl peptidase-4 (DPP-4) enzymatic destruction, which renders it inactive within a few minutes of its release. Exogenous GLP-1 analogs such as exenatide, lixisenatide, and liraglutide are resistant to the DPP-4 enzyme and have proven beneficial in managing obese T2DM patients. Pharmacotherapy aimed at inhibiting DPP-4 prolongs the action of endogenous GLP-1 and thus improves glycemic control.

### DPP-4 inhibitors

Gliptins (sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin) are oral incretin-based therapies. They are licensed for use as monotherapy or in combination with sulfonylureas, metformin, thiazolidinediones, and insulin. DPP-4 inhibitors bind to the catalytic site of the DPP-4 molecule and prevent the enzymatic degradation and inactivation of endogenous GLP-1.

The past 5 years of clinical experience with sitagliptin (the first approved DPP-4 inhibitor) has proved it to be well tolerated and safe. Several studies have demonstrated a reduction in HbA1c of up to 1%, and they are weight neutral. Most of the studies have not specifically looked into the effect of sitagliptin on elderly populations. With the increasing numbers of elderly people who also have T2DM, we will eventually need specific studies involving this group. At the moment, the beneficial effects seen in younger populations are extrapolated into the elderly group, and treatment indications and goals remain unchanged.

The most common side effects of gliptins are upper respiratory tract infections, headaches, and nasopharyngitis. Very rarely, severe side effects including renal failure and rhabdomyolysis have been noted; however, these are rare enough to be published as isolated case reports.

### Sitagliptin

Sitagliptin was the first DPP-4 inhibitor used in clinical practice. It is a phosphate monohydrate and is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate (1:1) monohydrate. It has high affinity for the DPP-4 enzyme and it reaches steady plasma concentrations after 3 days of administration. After oral administration of a single dose, it is absorbed with maximum plasma levels reached in 1–2 hours and has a half-life of 12 hours. It has 87% bioavailability after a single oral dose of 100 mg. Pharmacokinetic studies have shown that sitagliptin achieved an inhibition of 80% of DPP-4 enzyme after a single dose of 100 mg, and its effect lasted for more than 24 hours. It increased the plasma GLP-1 levels by two-fold compared with placebo.

A study by Vincent et al demonstrated that after a single dose of radiolabelled sitagliptin orally, the majority of sitagliptin (87%) was excreted unchanged in urine. It is excreted through both glomerular filtration and secretion into tubules. The remainder is metabolized by CYP 3A4 and CYP 2C8 enzymes and excreted in feces. In doses of 50–200 mg/day, more than 80% of DPP-4 enzyme is inhibited. This enables a two- to three-fold increase in endogenous GLP-1, thus augmenting its insulinotropic and glucagon-inhibiting effects.

Sitagliptin has been shown to provide effective fasting and postprandial glycemic control in a wide range of patients with T2DM. Markers of β-cell function (HOMA-β and proinsulin/insulin ratio) are also improved with sitagliptin treatment. The data until now have shown a significantly lower incidence of hypoglycemia with sitagliptin where used as monotherapy or as add-on to nonhypoglycemia-causing oral agents. However, when combined with a sulfonylurea, the risk of hypoglycemia increases to 12%, as opposed to 1.8% with monotherapy. Vilsbøll et al have reported increased incidence of hypoglycemia (16%) when sitagliptin is added to insulin in comparison with placebo (8%) and insulin.

### Clinical trials with sitagliptin

**Sitagliptin monotherapy**

As the first DPP-4 inhibitor available for treatment, sitagliptin has been extensively trialed and has proven effective and safe (see Table 2). The trials have been carried out in most population groups, and results have been unequivocal in demonstrating a significant reduction in HbA1c with minimal adverse events. Sitagliptin can be initiated as first line in patients intolerant to metformin and who need only a modest decrease in HbA1c to achieve target control. The advantages are a low risk of hypoglycemia, weight neutrality, and a possible improvement in β-cell dysfunction.

Aschner et al conducted a randomized, double-blind, placebo-controlled study in which 741 patients with a mean baseline HbA1c of 8.0% were allocated to sitagliptin 100 mg or 200 mg or placebo for 24 weeks. Sitagliptin 100 mg and 200 mg showed significant reductions in HbA1c of −0.79% and −0.94%, respectively, in comparison with placebo. Fasting and 2-hour postprandial glucose were also reduced in the sitagliptin group. There was no significant hypoglycemia and no change in baseline body weight with sitagliptin. Patients with higher baseline HbA1c showed the
best reductions in HbA1c levels. The study also showed that β-cell function and proinsulin/insulin ratio improved whilst on sitagliptin therapy.

Raz et al39 assessed the efficacy of sitagliptin in drug-naïve T2DM patients with HbA1c of ≥7% to ≥10%. A total of 521 patients with a mean baseline of HbA1c 8.1% were randomized in a 1:2:2 ratio to treatment with placebo, sitagliptin 100 mg once daily, or sitagliptin 200 mg once daily for a study duration of 18 weeks. The HbA1c reductions were −0.60% and −0.48% with sitagliptin 100 mg and 200 mg, respectively. Those patients with higher baseline HbA1c once again showed the maximum reductions in

<table>
<thead>
<tr>
<th>Trial</th>
<th>Number</th>
<th>Duration in weeks</th>
<th>Intervention</th>
<th>Reduction glycated hemoglobin (%)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aschner et al38</td>
<td>741</td>
<td>24</td>
<td>S100</td>
<td>−0.79</td>
<td>β-cell function improved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>S200</td>
<td>−0.94</td>
<td></td>
</tr>
<tr>
<td>Raz et al39</td>
<td>521</td>
<td>18</td>
<td>S100</td>
<td>−0.60</td>
<td>β-cell function improved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>S200</td>
<td>−0.48</td>
<td></td>
</tr>
<tr>
<td>Scott et al40</td>
<td>743</td>
<td>12</td>
<td>S2.5 od</td>
<td>Reductions in all groups</td>
<td>Maximum reduction with 50 mg bid</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>S12.5 od</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>S25 od</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldstein et al41</td>
<td>1,091</td>
<td>24</td>
<td>S100</td>
<td>−0.83</td>
<td>Additive hypoglycemic effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>S100 + M1000</td>
<td>−1.57</td>
<td>with combination therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>S100 + M2000</td>
<td>−2.07</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M1000</td>
<td>−0.99</td>
<td></td>
</tr>
<tr>
<td>Nonaka et al42</td>
<td>151</td>
<td>12</td>
<td>S100</td>
<td>−0.65</td>
<td>Significantly reduced 2-hour</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>postprandial glucose</td>
</tr>
<tr>
<td>Mohan et al44</td>
<td>530</td>
<td>18</td>
<td>S100</td>
<td>−1.0</td>
<td>Significantly reduced 2-hour</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>postprandial glucose</td>
</tr>
<tr>
<td>Charbonnel et al47</td>
<td>701</td>
<td>24</td>
<td>M ≥ 1,500</td>
<td>−0.65</td>
<td>β-cell function improved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on S100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott et al48</td>
<td>273</td>
<td>18</td>
<td>M ≥ 1,500</td>
<td>−0.73</td>
<td>≥3 kg weight gain in 21%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on S100</td>
<td></td>
<td>glitazone-treated group vs 2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M ≥ 1,500</td>
<td>−0.79</td>
<td>sitagliptin group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on R8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nauck et al49</td>
<td>1,172</td>
<td>52</td>
<td>M ≥ 1500</td>
<td>−0.67</td>
<td>Hypoglycemia rate was 5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on S100</td>
<td></td>
<td>with sitagliptin vs 32% in</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M ≥ 1500</td>
<td>−0.67</td>
<td>glipizide group</td>
</tr>
<tr>
<td>Pérez-Monteverde et al52</td>
<td>492</td>
<td>18 phase A</td>
<td>S100</td>
<td>−1.0</td>
<td>Weight reduction with S + M</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>28 phase B</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>P15–30</td>
<td>−0.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>S + M (50/1000 bid)</td>
<td>−1.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>P45</td>
<td>−1.4</td>
<td></td>
</tr>
<tr>
<td>Hermansen et al46</td>
<td>441</td>
<td>24</td>
<td>Gm + M</td>
<td>−0.89</td>
<td>Higher incidence of hypoglycemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on S100</td>
<td></td>
<td>when sitagliptin is added to</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gm</td>
<td>−0.57</td>
<td>sulfonylurea</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on S100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenstock et al48</td>
<td>175</td>
<td>24</td>
<td>P30–45</td>
<td>−0.70</td>
<td>Well tolerated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on S100</td>
<td></td>
<td>Low risk of hypoglycemia</td>
</tr>
<tr>
<td>Fonseca et al54</td>
<td>313</td>
<td>26</td>
<td>M ≥ 1500 + P ≥ 30</td>
<td>0.70</td>
<td>Well tolerated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Add on S100</td>
<td></td>
<td>Low risk of hypoglycemia</td>
</tr>
<tr>
<td>Sitagliptin use in chronic kidney disease</td>
<td>91</td>
<td>54</td>
<td>S25–50</td>
<td>−0.70</td>
<td>Well tolerated in chronic renal</td>
</tr>
<tr>
<td>Chan et al53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>impairment</td>
</tr>
<tr>
<td>Arjona Ferreira et al60</td>
<td>426</td>
<td>54</td>
<td>S25–50</td>
<td>Sitagliptin noninferior to glipizide</td>
<td>Higher hypoglycemia risk with</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GL2.5–20</td>
<td></td>
<td>glipizide</td>
</tr>
<tr>
<td>Arjona Ferreira et al61</td>
<td>129</td>
<td>54</td>
<td>S25</td>
<td>−0.72</td>
<td>Well tolerated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GL2.5–20</td>
<td>−0.89</td>
<td>Low risk of hypoglycemia compared with glipizide</td>
</tr>
</tbody>
</table>

Abbreviations: bid, twice daily; GL, glipizide; Gm, glimepiride; M, metformin; od, once daily; P, pioglitazone; R, rosiglitazone; S, sitagliptin.
HbA$_1c$ levels. The study also showed that β-cell function and proinsulin/insulin ratio improved whilst on sitagliptin therapy. Sitagliptin remained weight neutral.

Scott et al$^{40}$ assessed the efficacy of sitagliptin in 743 treatment-naïve T2DM patients in a randomized, double-blind, placebo- and active-controlled study. Patients were randomized to one of the six treatment arms (placebo, sitagliptin 5 mg once daily, 12.5 mg once daily, 25 mg once daily, or 50 mg twice a day, or a titrating dose of glipizide 5–20 mg/day) for 12 weeks. The mean baseline HbA$_1c$ of 7.9% improved in sitagliptin-treated patients by −0.38% to −0.77% in a dose-dependent manner (the highest reduction was in the sitagliptin 50 mg twice-daily group) in comparison with placebo. The glipizide group showed a −1% reduction in HbA$_1c$. However, hypoglycemia was significantly higher in the glipizide group (17%) compared with the sitagliptin group (2%). As in other studies, sitagliptin was well tolerated and weight neutral.

Goldstein et al$^{41}$ assessed the efficacy and safety of initial combination therapy with sitagliptin and metformin in 1,091 treatment-naïve patients with T2DM. Of the six treatment arms, one of them was sitagliptin 100 mg once daily, and the other two were combinations of sitagliptin 100 mg with either metformin 1000 mg or 2000 mg. The remaining groups were metformin 1000 mg/day or metformin 2000 mg/day or placebo. The mean baseline HbA$_1c$ was 7.5%–11%. After 24 weeks, HbA$_1c$ reductions of −0.83% to −2.07% were noted, with the highest reduction seen with combination therapy of sitagliptin 100 mg plus metformin 2 mg/day. Sitagliptin 100 mg once daily was associated with a −0.8% reduction in HbA$_1c$ from baseline. The treatment was well tolerated, with hypoglycemia rates similar to those seen with placebo. Metformin-treated patients had increased gastrointestinal side effects as expected.

Qi et al$^{42}$ have followed up the aforementioned cohort and reported on efficacy of sitagliptin after a total of 2 years treatment. The use of sitagliptin as monotherapy and in combination with metformin contributed to substantial reductions in HbA$_1c$ (−1.41% to −1.7% reduction from baseline).

Nonaka et al$^{43}$ performed a multicenter, double-blind, randomized, placebo-controlled trial in 151 T2DM patients in Japan. The baseline HbA$_1c$ was 6.5% to 10%, and they were randomized to sitagliptin 100 mg once daily or placebo for 12 weeks. The sitagliptin-treated group achieved statistically significant reduction in HbA$_1c$ and fasting plasma glucose in comparison with placebo. There was no hypoglycemia or weight change reported with sitagliptin.

Mohan et al$^{44}$ reported a randomized, placebo-controlled, double-blind study conducted on Indian, Chinese, and Korean populations. A total of 530 treatment-naïve T2DM patients with mean baseline HbA$_1c$ of 8.7% were randomized to sitagliptin 100 mg once daily or placebo. At the end of the 18-week trial period, the sitagliptin group achieved a statistically significantly reduction in HbA$_1c$ (−1%) compared with the placebo group. Fasting and postprandial glucose reductions were also statistically significantly reduced. No hypoglycemia was reported and the drug was well tolerated.

Hanefeld et al$^{45}$ conducted a multinational, double-blind, randomized, placebo-controlled, parallel-group, dose-range-finding study. A total of 555 patients with HbA$_1c$ ranging between 6.5% and 10.0% were randomized to one of five treatment groups: placebo; sitagliptin 25 mg, 50 mg, or 100 mg once daily; or sitagliptin 50 mg twice daily for 12 weeks. A mean HbA$_1c$ reduction of −0.39% to −0.56% was seen across all doses of sitagliptin in comparison with placebo. Fasting plasma glucose was reduced and HOMA-β was significantly raised in the sitagliptin group, with no change in quantitative insulin sensitivity check index (QUICKI) and HOMA-IR. Sitagliptin was well tolerated and with few hypoglycemic episodes.

All these studies have shown overall improvements in glycemic control with no significant hypoglycemia. Sitagliptin can be used in selected patient groups as first-line agent or as monotherapy.

**Sitagliptin in combination or add-on therapy**

Sitagliptin is preferred as an add-on therapy or second-line agent in T2DM patients at risk of hypoglycemia. The risk of hypoglycemia is higher when used in combination with sulfonylurea. Hence, patients who will benefit by such a combination should be carefully selected. It can also be used in combination with thiazolidinediones and insulin. Both the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) have issued position statements for recommending DPP4 inhibitor use in combination with metformin and further second- or third-line agents. It is also recommended for use with basal insulin therapy.$^{46}$

**With metformin**

Charbonnel et al$^{47}$ conducted a 24-week randomized controlled study on 701 T2DM patients established on metformin ≥1,500 mg/day but with inadequate glycemic control (≥7% to ≤10%). Patients were randomized to placebo...
or sitagliptin 100 mg/day in a ratio of 1:2 for 24 weeks. Sitagliptin use was associated with a significant reduction in HbA1c (mean -0.65%) in comparison with placebo (mean -0.02%). Apart from improved glycemic control, sitagliptin use resulted in significant increase in markers for β-cell function (fasting insulin, fasting C-peptide, homeostasis model assessment of β-cell function, and QUICKI). The fasting proinsulin/insulin ratio was reduced by the end of the trial, and a small but statistically significant improvement was noted in the lipid profile with sitagliptin. Hypoglycemia was similar in both groups. However, nasopharyngitis was higher with sitagliptin.

Scott et al58 have assessed the addition of sitagliptin to 273 T2DM patients established on only metformin ≥1,500 mg/day but with inadequate glycemic control (7%–11%). They were randomized to placebo, sitagliptin 100 mg, or rosiglitazone 8 mg in a 1:1:1 ratio and evaluated for outcomes after 18 weeks. The improvement in glycemic control was similar in the sitagliptin and glitazone groups (-0.79% vs -0.73%). However, weight gain was seen in 21% of the glitazone group compared with 2% with sitagliptin. Hypoglycemia was similar between all intervention groups. Currently, pioglitazone is the only glitazone being actively used, and it may be unfair to assume similar results with this agent.

Nauck et al59 conducted a 52-week noninferiority trial comparing the addition of sitagliptin 100 mg/day (n = 588) or glipizide 5 mg/day (n = 584, with dose titration to maximum 20 mg/day) to patients established on metformin ≥1,500 mg/day but with inadequate glycemic control (≥6.5% to ≤10%). The mean HbA1c of the cohort at baseline was 7.5%, and at the end of the trial, both the groups showed a reduction of -0.67% in HbA1c. The trial achieved its primary goal of establishing that sitagliptin is noninferior to glipizide in achieving glycemic control, but glipizide was associated with a significantly higher rate (32%) of hypoglycemic events compared with very few (2%) with sitagliptin. In addition, sitagliptin did not cause weight gain as glipizide did, and it actually contributed to weight loss (~1.5 kg from baseline). This trial was continued for a total of 2 years, the beneficial effects of sitagliptin persisted, and it was well tolerated. β-cell function was preserved with sitagliptin as opposed to a decrease in the glipizide group.

Lim et al51 assessed the efficacy of adding combination therapy of metformin and sitagliptin to drug-naïve T2DM patients with low β-cell function. They noted significant improvement in HbA1c from baseline (from 8.7% ± 1.4% to 7.2% ± 1.3%). Fasting plasma glucose and markers of β-cell function also improved, suggesting beneficial effects of adding sitagliptin as initial therapy.

Pérez-Monteverde et al52 have conducted an interesting study to demonstrate the beneficial effects of sitagliptin and metformin combinations when compared with pioglitazone alone. They randomized 492 treatment-naïve T2DM patients with baseline HbA1c of 7%–12.5% in the ratio of 1:1 to either sitagliptin 100 mg once daily or pioglitazone 15 mg (dose increased to 30 mg after 6 weeks). After 18 weeks of initial treatment, the sitagliptin group was switched to a combination of sitagliptin 50 mg and metformin 1 mg twice daily (dose titrated upwards over 4 weeks). The pioglitazone group increased the dose to 45 mg/day. They found that in the initial 18-week monotherapy period, the HbA1c reduction in both groups was similar. However, with the addition of metformin to sitagliptin in the second phase of the study, there was numerically improved HbA1c, fasting glucose, and postprandial glucose levels in this combination group. The hypoglycemic events were low in both groups and numerically similar. Weight loss was noted in the sitagliptin/metformin combination as opposed to weight gain in the pioglitazone group.

Olansky et al53 have reported on a trial in which an initial fixed-dose combination of metformin and sitagliptin was compared with metformin alone and following addition of other oral hypoglycemic agents. A total of 8.8% in the fixed drug group and 16.7% of the metformin alone group needed an additional oral hypoglycemic agent. The fixed combination group showed a statistically significant reduction in HbA1c compared with the initial metformin only group (least-squares mean change -2.3% vs -1.8%, respectively). The target HbA1c of <7% was reached by a significantly higher proportion of patients in the sitagliptin and metformin combination group. This study has shown advantages of initial combination therapy over monotherapy.

With sulfonylureas

Hermansen et al54 have studied the efficacy of the addition of sitagliptin 100 mg/day or placebo to 441 T2DM patients on glimepiride ≥4 mg/day monotherapy (n = 212) or glimepiride ≥4 mg/day with metformin ≥1,500 mg/day (n = 229). The cohort had inadequate glycemic control (≥7.5% to ≤10.5%) at baseline, and the mean HbA1c was 8.34%. Members of the study population who exceeded the predetermined upper limits of glycemic control were offered pioglitazone as rescue therapy. After 24 weeks, the mean HbA1c reduced with sitagliptin was -0.74% compared with placebo. Patients on sitagliptin and glimepiride plus metformin had a drop of 0.89% compared with a reduction
of 0.57% in the sitagliptin plus glimepiride group. The addition of sitagliptin improved fasting and postprandial blood glucose significantly; markers of β-cell function were also improved at the end of 24 weeks. Hypoglycemia rates were significantly higher in the sitagliptin group compared with placebo, consistent with the use of a sulfonfonyurea.

With pioglitazone
Rosenstock et al34 conducted a 24-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of adding sitagliptin 100 mg versus placebo to T2DM patients established on pioglitazone 30–45 mg/day. In the 8 to 14-week pretrial period, the participants who were on different antihyperglycemics were changed to pioglitazone and dose titrated to 30–45 mg/day. Patients were randomized in a 1:1 ratio to receive sitagliptin 100 mg (n = 175) or placebo (n = 178) over the next 24 weeks. The primary end point was improvement in HbA1c from baseline. The secondary end points were change in fasting plasma glucose, effect on markers of β-cell function, and the need for rescue metformin therapy. The mean baseline HbA1c was 8.1% in the sitagliptin group versus 8% in the placebo group. At the end of 24 weeks, significant HbA1c reductions (least-squares mean change of −0.70%) were noted with sitagliptin. Mean HbA1c values at the end point were 7.2% (0.9) and 7.8% (1.1) in the sitagliptin and placebo treatment groups, respectively. Sitagliptin was well tolerated with no significant hypoglycemia and remained weight neutral.

With metformin and glitazones as triple therapy
According to the current guidelines, DPP-4 inhibitors can be introduced as a monotherapy or add-on therapy quite early in the treatment plan.

Arjona Ferreira et al35 conducted a trial adding in sitagliptin to ongoing treatment with metformin (≥1,500 mg/day) and rosiglitazone (≥4 mg/day). A total of 278 patients were randomized to sitagliptin 100 mg/day or placebo in a 2:1 ratio. At the end of 18 weeks, patients treated with sitagliptin resulted in an average 0.9% reduction in HbA1c compared with baseline. Patients with higher HbA1c at baseline showed greater reductions. Fasting plasma glucose, 2-hour postprandial glucose, and markers of β-cell function were significantly improved at the end of study when compared with placebo.

Fonseca et al36 conducted a randomized, placebo-controlled, double-blind study in 313 T2DM patients with inadequately controlled HbA1c (≥7.5% to ≤11%) on metformin ≥1,500 mg/day and pioglitazone ≥30 mg/day. They were randomized to sitagliptin 100 mg once daily or placebo. The addition of sitagliptin resulted in a significant reduction in HbA1c compared with placebo. It was well tolerated with few hypoglycemic episodes in both arms of the study.

Sitagliptin and CKD
Diabetes is the most common cause of CKD. This important and inevitable complication in most of the poorly controlled T2DM patients poses therapeutic challenges. The risk of hypoglycemia with sulfonfonyureas and insulin is higher in this group. Sitagliptin is licensed to be used with appropriate dose reductions.

Bergman et al57,58 have studied the effect of renal insufficiency on the pharmacokinetics of sitagliptin in a Phase III trial. The effect of a single oral dose of sitagliptin 50 mg was evaluated in various degrees of renal insufficiency (n = 6 in each group): mild (creatinine clearance [CrCl], 50–80 mL/min), moderate (CrCl, 30–50 mL/min), and severe (CrCl, <30 mL/min). Patients with end-stage renal failure on hemodialysis received single-dose sitagliptin 50 mg and had dialysis 4 hours postdose. After a washout period of 1 week, the same group of ESRD patients received a single dose of sitagliptin 50 mg, and hemodialysis was performed 48 hours later. The control group was subjects with normal renal function.

The area under the curve (AUC) for sitagliptin was less than two times normal in mild renal impairment, which was acceptable according to the predetermined value. In patients with CKD stages 3–5, including those on hemodialysis, plasma AUC levels were increased by approximately 2.5–4.5 times. This also corresponded to an increased maximum plasma concentration (C max) and an increased terminal half-life of up to 22.5 hours with severe renal impairment.

During hemodialysis, 13.5% and 3.5% of sitagliptin was removed after a dialysis session 4 hours and 48 hours after oral administration, respectively. The study concluded that to achieve similar plasma concentrations of sitagliptin to those in patients without renal insufficiency, moderate renal impairment (eGFR 30–50 mL) should receive 50 mg/day, and severe renal impairment (eGFR <30 mL) or ESRD on hemodialysis patients should receive 25 mg/day. There is no need for reduction of dose in mild renal impairment (eGFR >50 mL). Chan et al59 conducted a 54-week safety and efficacy trial of sitagliptin over 54 weeks in patients with CKD stages 3–5, including ESRD patients on hemodialysis. It was a randomized, double-blind, parallel-group study.
A total of 91 patients were randomized in a 2:1 ratio to sitagliptin (n = 65) or the sequence of placebo (initial 12 weeks) and glipizide (from the 13th week to 54 weeks, n = 26). The dose of sitagliptin was reduced to 50 mg/day or 25 mg/day in moderate and severe renal impairment, respectively. Glipizide was started at 2.5 mg/day and titrated to a maximum of 20 mg/day.

The mean baseline HbA1c was 7.7% (range 6.2%–10%) and it was reduced by −0.6% after 12 weeks and −0.7% after 54 weeks in the sitagliptin group. The hypoglycemia rate was significantly lower in the sitagliptin group (4.6%) compared with the placebo/glipizide group (23.1%). Sitagliptin was well tolerated and safe in CKD stages 3–5, including patients with ESRD on dialysis.

The largest study to date assessing the efficacy and safety of sitagliptin in patients with CKD stages 3–5 was reported recently by Arjona Ferreira et al. They studied a total of 426 patients randomized in a ratio of 1:1 to sitagliptin (50 mg/day in moderate renal impairment and 25 mg/day in severe renal impairment) or glipizide (started at 2.5 mg/day and titrated up to 20 mg/day). After 54 weeks, sitagliptin was noninferior to glipizide in reducing HbA1c. There was, however, a significant difference in the incidence of hypoglycemia, with 17% in the glipizide group as opposed to 6.2% with sitagliptin. Glipizide intervention was also associated with weight gain (1.2 kg), whereas the sitagliptin group showed a decrease in body weight (0.6 kg). Hence, sitagliptin at a reduced dose was safe, well tolerated, and largely remained weight neutral.

**Sitagliptin and ESRD on hemodialysis**

A randomized, double-blind, parallel-arm study specifically in 129 ESRD patients on hemodialysis comparing the efficacy and safety of sitagliptin and glipizide is completed and awaiting publication. The patients were randomized 1:1 to either sitagliptin 25 mg/day or glipizide 2.5 mg titrated to a maximum of 10 mg to avoid hypoglycemia. The primary end point was to look into improvement in HbA1c at the end of 54 weeks of treatment. The least-squares mean changes in HbA1c from baseline in the sitagliptin- and glipizide-treated groups were −0.72% and −0.87%, respectively. The symptomatic hyperglycemia rate was 6.3% with sitagliptin and 10.8% with glipizide. Severe hyperglycemia was significantly more frequent with glipizide (7.7%), there being no episodes with sitagliptin. Sitagliptin was well tolerated at this dose, and, overall, adverse events and discontinuation rates were similar between the therapies.

The results until now are convincing enough to suggest the safety of sitagliptin use in CKD with appropriate dose adjustments. Hypoglycemia rates were significantly less when compared with sulfonylureas.

**Use of sitagliptin and effect on clinical outcomes**

The cornerstone of diabetes management is to achieve good glycemic control, which will lead to beneficial cardiovascular outcomes. Some studies that have evaluated this have suggested that cardiovascular morbidity is reduced with use of DPP-4 inhibitors. A meta-analysis of 18 randomized studies, which included 4,998 patients on DPP-4 inhibitors, was compared with a comparator group of 3,456 on other oral agents. The median duration of these studies was 46 weeks. The relative risk for any cardiovascular event was 0.48 and for nonfatal myocardial infarction was 0.40. This meta-analysis concluded that DPP-4 inhibitors possibly decrease cardiovascular end points.

However, a large, retrospective, population-based cohort study (n = 72,738) analyzed whether sitagliptin (n = 8,032) use offered any benefit in cardiovascular outcomes or all-cause mortality when compared with other oral antidiabetic agents (n = 64,806). The study showed no difference in the outcome between the two groups. The use of DPP-4 inhibitors is only recent, and long-term follow-up studies are needed to shed more light on cardiovascular outcomes.

**Conclusion**

Sitagliptin was the first DPP-4 inhibitor to be used in clinical practice, being licensed in 2006. The clinical experience of its use up until now has shown it to be beneficial in improving glycemic control as a monotherapy or as an add-on to metformin, pioglitazone, or sulfonylurea. It has also proved effective in triple therapy. The low risk of hypoglycemia and its weight-neutral properties makes it a preferred choice compared with sulfonylurea or thiazolidinediones in many scenarios. It is approved to be used with insulin and, as recognized, the hypoglycemia risk is higher with this combination, which can be avoided by insulin dose titration.

The most important recent progress is the use of sitagliptin in CKD, including ESRD patients on hemodialysis. The majority of sitagliptin is excreted unchanged following glomerular filtration. Hence, there is the potential for accumulation of drug in CKD. With appropriate reduction of its dose (25–50 mg/day), it has been shown to be safe and effective in achieving reduction in HbA1c in this group.
Disclosure

SC Bain has received honoraria, teaching and research sponsorship from the following: Abbott, Astra-Zeneca, Boehringer Ingelheim, BMS, Diastis, Eli Lilly, GlaxoSmith-Kline, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-aventis, Schering-Plough, Servier & Takeda. The authors report no other conflicts of interest in this work.

References

30. JANUVIA (sitagliptin) [prescribing information]. Whitehouse Station, NJ: Merck and Co, Inc.


